Ansbert Gadicke Cullinan Oncology, Inc. (CGEM) insider trading activity

CGEM Quotes by TradingView

Ansbert Gadicke is Director of Cullinan Oncology, Inc.. Currently has a direct ownership of 244,551 shares of CGEM, which is worth approximately $3.07 Million. The most recent transaction as insider was on Sep 16, 2021, when has been sold 432 shares (Common Stock) at a price of $29.06 per share, resulting in proceeds of $12,554. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 245K
0% 3M change
0% 12M change
Total Value Held $3.07 Million

ANSBERT GADICKE Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 16 2021
SELL
Open market or private sale
$12,554 $29.06 p/Share
432 Reduced 0.18%
244,551 Common Stock
Sep 15 2021
SELL
Open market or private sale
$25,894 $29.16 p/Share
888 Reduced 0.36%
244,983 Common Stock
Sep 14 2021
SELL
Open market or private sale
$28,645 $29.17 p/Share
982 Reduced 0.4%
245,871 Common Stock
Sep 13 2021
SELL
Open market or private sale
$14,463 $29.1 p/Share
497 Reduced 0.2%
246,853 Common Stock
Sep 10 2021
SELL
Open market or private sale
$23,813 $29.04 p/Share
820 Reduced 0.33%
247,350 Common Stock
Sep 09 2021
SELL
Open market or private sale
$55,706 $29.35 p/Share
1,898 Reduced 0.76%
248,170 Common Stock
Sep 08 2021
SELL
Open market or private sale
$43,636 $29.11 p/Share
1,499 Reduced 0.6%
250,068 Common Stock
Sep 07 2021
SELL
Open market or private sale
$100,624 $29.04 p/Share
3,465 Reduced 1.36%
251,567 Common Stock
Sep 03 2021
SELL
Open market or private sale
$52,096 $29.6 p/Share
1,760 Reduced 0.69%
255,032 Common Stock
Sep 02 2021
SELL
Open market or private sale
$64,164 $29.46 p/Share
2,178 Reduced 0.84%
256,792 Common Stock
Sep 01 2021
SELL
Open market or private sale
$23,281 $29.47 p/Share
790 Reduced 0.3%
258,970 Common Stock
Aug 31 2021
SELL
Open market or private sale
$11,678 $29.79 p/Share
392 Reduced 0.15%
259,760 Common Stock
Aug 30 2021
SELL
Open market or private sale
$125,550 $29.3 p/Share
4,285 Reduced 1.62%
260,152 Common Stock
Aug 27 2021
SELL
Open market or private sale
$53,700 $29.09 p/Share
1,846 Reduced 0.69%
264,437 Common Stock
Aug 25 2021
SELL
Open market or private sale
$6,894 $29.09 p/Share
237 Reduced 0.09%
266,283 Common Stock
Aug 24 2021
SELL
Open market or private sale
$207,097 $29.48 p/Share
7,025 Reduced 2.57%
266,520 Common Stock
Aug 23 2021
SELL
Open market or private sale
$214,715 $29.11 p/Share
7,376 Reduced 2.63%
273,545 Common Stock
Aug 11 2021
SELL
Open market or private sale
$10,080 $29.05 p/Share
347 Reduced 0.12%
280,921 Common Stock
Jan 07 2021
BUY
Other acquisition or disposition
-
281,268 Added 50.0%
281,268 Common Stock

Also insider at

ITOS
iTeos Therapeutics, Inc. Healthcare
> 10% Shareholder
ONCR
Oncorus, Inc. Healthcare
> 10% Shareholder
RPTX
Repare Therapeutics Inc. Healthcare
> 10% Shareholder
HARP
Harpoon Therapeutics, Inc. Healthcare
> 10% Shareholder
HOWL
Werewolf Therapeutics, Inc. Healthcare
> 10% Shareholder
ALVR
Allovir, Inc. Healthcare
Director
TCRR
TCR2 THERAPEUTICS INC. Healthcare
Director
AG

Ansbert Gadicke

Director
Waltham, MA

Track Institutional and Insider Activities on CGEM

Follow Cullinan Oncology, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CGEM shares.

Notify only if

Insider Trading

Get notified when an Cullinan Oncology, Inc. insider buys or sells CGEM shares.

Notify only if

News

Receive news related to Cullinan Oncology, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on CGEM